Effect of APOE genotype on microvascular basement membrane in Alzheimer's disease

S Salloway1, T Gur, T Berzin

  • 1Brown Medical School, Providence, RI, USA. Stephen_Salloway@brown.edu

Insights

Individuals with two copies of the APOE4 gene (APOE4,4) show reduced capillary basement membrane area in Alzheimer's disease (AD) brains. This finding suggests a link between APOE4 genotype and microvascular changes in AD pathogenesis.

Area of Science:

  • Neuroscience
  • Genetics
  • Pathology

Background:

  • Alzheimer's disease (AD) risk is linked to APOE4 homozygosity, but the underlying mechanism is unclear.
  • Microvascular basement membrane injury is implicated in AD-related dementia.
  • Agrin, a synaptic protein, is a key component of brain microvascular basement membranes.

Purpose of the Study:

  • To compare the basement membrane surface area of cortical microvasculature in AD brains based on APOE genotype.
  • To investigate the relationship between APOE4 status and microvascular integrity in AD.

Main Methods:

  • Cortical microvasculature was stained with an anti-agrin antibody in 35 AD cases genotyped for APOE status.
  • Quantitative morphometric analysis determined the mean capillary basement membrane area (CBMA).
  • APOE3,3 and APOE4,4 homozygotes, and APOE3,4 heterozygotes were compared.

Main Results:

  • APOE4,4 homozygotes exhibited significantly smaller CBMA (17.4 μm²) compared to APOE3,3 homozygotes (26.9 μm²).
  • CBMA in APOE3,4 heterozygotes did not differ significantly from either homozygote group.
  • Braak stage did not significantly affect CBMA, though a preliminary interaction with APOE4,4 and advanced Braak stages was noted.

Conclusions:

  • APOE4,4 genotype is associated with a thinner microvascular basement membrane in the brains of Alzheimer's disease patients.
  • These findings support a role for microvascular alterations in the pathogenesis of AD in APOE4 carriers.
  • Further research with larger samples is needed to confirm the interaction between APOE4,4 and Braak stage.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...